Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

For those that may not have the opportunity to be part of a clinical trial, Burke proceeds with a step-by-step process. Burke emphasizes that the first practical step is to educate oneself on the ...

Panelists discuss second-line treatment options and emerging approaches for HER2-mutated non–-small cell lung cancer (NSCLC), highlighting novel therapies and clinical strategies.

Panelists discuss the role of HER2 mutations in non–-small cell lung cancer (NSCLC), focusing on diagnostic approaches, clinical implications, and targeted treatment strategies.

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for ...

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

Bernd Kasper, MD, PhD, provides an overview of the phase 3 DeFi trial of nirogacestat for the treatment of patients with progressing desmoid tumors.

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer ...